Drug intelligence / Profile preview

Zhike Shuangjie

Development stage: Unknown
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Zhike Shuangjie is a Traditional Chinese Medicine (TCM) formulation developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is an oral powder indicated for the treatment of adult upper respiratory tract infections (URTI), specifically targeting URTI-related cough during the winter and spring seasons. The drug is being evaluated in the SMART trial (Phase 0), which compares its efficacy and safety against other TCM formulations (Zhike Baidu powder, Wensan tincture) and the leukotriene receptor antagonist montelukast sodium. As a TCM product, it likely contains a blend of botanical ingredients intended to clear heat, resolve exterior symptoms, and suppress cough.

Other names: Zhike Shuangjie powder

Beyond the preview

Go deeper on Zhike Shuangjie.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhike Shuangjie.

Explore the full profile